Literature DB >> 22391294

The effectiveness of hypertonic saline and pentoxifylline (HTS-PTX) resuscitation in haemorrhagic shock and sepsis tissue injury: comparison with LR, HES, and LR-PTX treatments.

Ho Jung Kim1, Kang Hyun Lee.   

Abstract

PURPOSE: To compare lung and liver injury and laboratory results in haemorrhagic shock and sepsis models treated with combinations of lactated Ringer's solution (LR), 7.5% hypertonic saline (HTS), hydroxyethyl starch (HES), and pentoxifylline (PTX).
METHODS: Male Sprague-Dawley rats (200-290 g) were assigned randomly to one of four treatment groups (n=16 per group): (1) LR; (2) HES; (3) LR-PTX; and (4) HTS-PTX. Each group was subdivided into (1) haemorrhagic shock (n=8) and (2) sepsis (n=8) model groups. A venous catheter was used to inject resuscitation fluids, and an arterial catheter was used to withdraw blood and monitor mean arterial pressure (MAP). Lung and liver histology, bronchoalveolar lavage (BAL) fluid, and cytokine levels were evaluated.
RESULTS: The mean lung injury score was 1.7. At 24h after treatment, the total leucocyte count in the BAL fluid was significantly (p<0.05) higher with LR treatment (10 × 10(6) ± 0.8) than with other treatments in the sepsis model groups (HES, 6 × 10(6) ± 1.2; LR-PTX, 5 × 10(6) ± 1.5; HTS-PTX, 5 × 10(6) ± 0.6). The higher total leucocyte count after LR treatment was attributable to a greater increase in the number of neutrophils (17 ± 1.5%) compared with increases after the other treatments (HES, 6 ± 0.8%; LR-PTX, 10 ± 1.3%; HTS-PTX, 5 ± 0.4%). In the sepsis model groups, the total hepatic injury score was also significantly (p<0.05) higher with LR treatment (9.9 ± 0.5) than with the other treatments (HES, 6.7 ± 0.8; LR-PTX, 5.6 ± 0.7; HTS-PTX, 3.1 ± 0.9). This also occurred in the shock model (LR, 10.6 ± 2.1; HES, 5.8 ± 0.9; LR-PTX, 7.3 ± 0.9; HTS-PTX, 3.5 ± 0.9). As compared with LR treatment, HTS-PTX resuscitation resulted in a 49% decrease in TNF-α, 29% decrease in IL-1β, and 58% decrease in IL-6 in the shock model at 24h (p<0.05), and the respective decreases were 45, 24, and 35% in the sepsis model (p<0.05).
CONCLUSION: HTS-PTX was superior to HES, LR-PTX, and LR for treating shock and sepsis, and LR-PTX and HES gave better results than LR therapy alone.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391294     DOI: 10.1016/j.injury.2012.02.005

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  5 in total

1.  Three hydrogen-rich solutions protect against intestinal injury in uncontrolled hemorrhagic shock.

Authors:  Zunmin Du; Jing Liu; Haipeng Jia; Wei Xu; Xiaomin Zhao
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Immunomodulation via MyD88-NFκB Signaling Pathway from Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury.

Authors:  Kang-Hsi Wu; Ju-Pi Li; Wan-Ru Chao; Yi-Ju Lee; Shun-Fa Yang; Ching-Chang Cheng; Yu-Hua Chao
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

3.  Impact of hypertonic saline on postoperative complications for patients undergoing upper gastrointestinal surgery.

Authors:  Siqi Hong; Qingjuan Shang; Qiankun Geng; Yang Yang; Yan Wang; Chunbao Guo
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Hypertonic saline and pentoxifylline enhance survival, reducing apoptosis and oxidative stress in a rat model of strangulated closed loop small bowel obstruction.

Authors:  Gustavo Scapini; Roberto Rasslan; Natalie Chaves Cayuela; Miguel Angelo Goes; Marcia Kiyomi Koike; Edivaldo Massazo Utiyama; Edna Frasson de Souza Montero; Samir Rasslan
Journal:  Clinics (Sao Paulo)       Date:  2019-06-06       Impact factor: 2.365

5.  Comparison of the effects of volemic reposition with 7.5% NaCl or blood in an experimental model of muscular compression and hemorrhagic shock.

Authors:  Mauricio Wanderley Moral Sgarbi; Bomfim Alves Silva Júnior; Daniel de Almeida Pires; Irineu Tadeu Velasco
Journal:  Rev Bras Ortop       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.